AstraZeneca pays $50 million for rights to Merck cancer drug
(Reuters) - Merck & Co Inc has licensed its experimental cancer drug to AstraZeneca Plc for a $50 million upfront fee in a deal that shows Britain's second-biggest drugmaker continuing to rebuild its pipeline.
Under the terms of the agreement, Merck, the No. 2 U.S. drugmaker, will also be eligible to receive future payments related to development and regulatory milestones, as well as tiered royalties.
The drug, MK-1775, is currently in mid-stage trials in combination with standard-of-care therapies for the treatment of patients with certain types of ovarian cancer.
(Reporting by Shailesh Kuber; Editing by Sreejiraj Eluvangal)
- Air strike kills 15 civilians in Yemen by mistake: officials
- North Korea executes leader's powerful uncle in rare public purge |
- Insight: In Yemen, al Qaeda gains sympathy amid U.S. drone strikes
- Twitter backtracks on block feature after users revolt |
- Iran angry over U.S. sanctions, nuclear talks interrupted
Thousands line up to say goodbye to Nelson Mandela, whose body is lying in state in Pretoria. Slideshow